Half-Life (Normalesrd) Hours
8-15/16-30
Plasma Protein Binding %
40
Volume Of Distribution L/Kg
0.7-0.8
Dose For Normal Renal Function
300-600 mg bid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75-100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose for GRF <10, give after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Decrease dose by 50%, monitor levels, [D]
References
Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia. 1994; 35 Suppl 3: S10-3. [PMID: 8156973] / Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol. 1994; 47: 161-7. [PMID: 7859804]
Toxicity Notes
Hyponatremia. Oxcarbazepine is extensively metabolized to its pharmacologically active 10-monohydroxy metabolite (MHD). MHD is responsible for most antiepileptic activity. Kinetic parameters are for MHD. Cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD. Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4/5 with potentially important effects on plasma concentrations of other drugs.